Related Articles
Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway
Integrin β1‑mediated acquired gefitinib resistance in non‑small cell lung cancer cells occurs via the phosphoinositide 3-kinase‑dependent pathway
miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway
Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway
Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines